{"public_id":"cl_a7c0db51987d0d014ce3e08ed45fec80","status":"active","superseded_by_public_id":null,"corpus_id":1545777,"text":"Time to dyskinesia favored ropinirole over levodopa, with a hazard ratio for remaining free of dyskinesia of 2.82.","confidence":0.95,"paper":{"corpus_id":1545777,"title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.","url":"https://sah.borca.ai/papers/1545777"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3b535a9153ac98acab67406a044d419b","name":"time to dyskinesia","description":"The duration from treatment initiation until dyskinesia occurred.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_3b535a9153ac98acab67406a044d419b"},{"public_id":"co_441939db84c180c031c67b8d5b1db92e","name":"ropinirole","description":"A dopamine D2-receptor agonist used as an initial treatment for early Parkinson's disease in the study.","types":["drug","dopamine agonist"],"url":"https://sah.borca.ai/concepts/co_441939db84c180c031c67b8d5b1db92e"},{"public_id":"co_7f147b3761f805e93f53fa2230affe8e","name":"levodopa","description":"A dopaminergic medication used as comparator and as supplementary open-label treatment when symptoms were not adequately controlled.","types":["drug","treatment"],"url":"https://sah.borca.ai/concepts/co_7f147b3761f805e93f53fa2230affe8e"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a7c0db51987d0d014ce3e08ed45fec80"}